NCT01519531CompletedPhase 1
A Randomized, Double-blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects
Madrigal Pharmaceuticals, Inc.1 site in 1 country48 target enrollmentStarted: January 2012Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 48
- Locations
- 1
- Primary Endpoint
- Number of Adverse Events as a measure of safety and tolerability of VIA-3196
Study Overview
Brief Summary
This is a single-center, randomized, double-blind, placebo-controlled, ascending multiple-dose study of VIA-3196 to evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects. Study dosing is organized into cohorts corresponding to escalating doses of VIA-3196 or matching placebo. Subjects will be dosed daily for 14 days.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •The subject must be willing and able to provide written informed consent.
- •Healthy, non-smoking, males and females between the ages of 18 and 55 years of age (inclusive).
- •If female, the subject is of non-child bearing potential (i.e., surgically [bilateral oophorectomy, hysterectomy, or tubal ligation] or naturally sterile [>12 consecutive months without menses]). Verify by FSH at screening as appropriate.
- •Body weight > 50 kg and BMI between 18 and 30 kg/m2 (inclusive).
- •LDL cholesterol ≥ 110mg/dL.
Exclusion Criteria
- •History of thyroid disorder or abnormal thyroid function tests at screening. Repeat testing is allowed once at the discretion of the Investigator. - History of unexplained syncope.
- •History of hepatobiliary disease; or AST, ALT or direct bilirubin greater than the upper limit of reference range at screening.
- •Positive screening test for HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody.
- •Abnormal screening ECG: including machine-read QTc >450 msec (confirmed by manual over read), QRS >110 msec, intermittent bundle branch block, frequent premature atrial or premature ventricular contractions, or any rhythm other than normal sinus rhythm which is interpreted by the Investigator to be clinically significant.
- •History of sensitivity to a similar study drug (e.g., Karo Bio KB2115 or Metabasis MB7811), or a history of important drug or other allergy (except for untreated, asymptomatic seasonal allergies at time of dosing) unless deemed not clinically significant by the Investigator.
- •History of sensitivity to thyroid medication.
- •History of asthma, or intolerance to beta-blockers.
- •Use of acetaminophen within 7 days before dosing and throughout the study.
- •History of regular use of tobacco or nicotine containing products within the past 6 months.
- •Positive urine drug screen or alcohol test at screening or Day -1.
Arms & Interventions
VIA-3196
Experimental
Intervention: VIA-3196 (Drug)
Placebo
Placebo Comparator
Multiple, ascending dosing groups (cohorts) will be evaluated.
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Number of Adverse Events as a measure of safety and tolerability of VIA-3196
Time Frame: up to 22 days
Evaluation will start from predose (Day -1) until the follow-up visit (Day 21)
Secondary Outcomes
- Plasma concentration of VIA-3196(0 to 24 hours on Day 1 and Day 14)
- Lipid level changes following administration of VIA-3196(Day 1 to 14)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy VolunteersChronic PainNCT05714254AstraZeneca36
Completed
Phase 1
Voclosporin in Healthy Japanese VolunteersVolunteersNCT02949999Aurinia Pharmaceuticals Inc.40
Completed
Phase 1
A Clinical Trial of BGT-002 Tablets in Subjects With Nonalcoholic SteatohepatitisNASHNCT06491576Burgeon Therapeutics Co., Ltd.48
Completed
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT02391259Amgen57
Terminated
Phase 1
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)Atopic DermatitisNCT05859724Yellow Jersey Therapeutics AG126